Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Role of Genotype in the Cycle of Violence in Maltreated Children
2002 StandoutScience
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Extracellular Matrix Reorganization During Wound Healing and Its Impact on Abnormal Scarring
2013 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Parenteral Anticoagulants
2012 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Child abuse: Adolescent records vs. adult recall
1990 Standout
Newer Pharmacotherapy in Patients Undergoing Percutaneous Coronary Interventions: A Guide for Pharmacists and Other Health Care Professionals
2006
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010 Standout
Haemostatic materials for wound healing applications
2021 Standout
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
2013 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
New oral antithrombotics: a need for laboratory monitoring. For
2010
Prospects for Cardiovascular Research
2001 StandoutNobel
Oral Anticoagulant Therapy
2012 Standout
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
2003 Standout
Combined Screening With Ultrasound and Mammography vs Mammography Alone in Women at Elevated Risk of Breast Cancer
2008 Standout
Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: Cosponsored by american association of clinical endocrinologists, The obesity society, and american society for metabolic & bariatric surgery*
2013 Standout
Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus
1999
Effects of extracellular matrix viscoelasticity on cellular behaviour
2020 StandoutNature
Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and chlamydia pneumoniae
2004
An update on bioactive plant lignans
2005 Standout
The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients
2003
Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: Results of the STACK-on to ENOXaparin (STACKENOX) study
2009
Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads
2012
Decorin synthesized by arterial smooth muscle cells is retained in fibrin gels and modulates fibrin contraction
2007
Usefulness of a Highly Sensitive Urinary and Serum IL-6 Assay in Patients with Diabetic Nephropathy
2000
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
2004 Standout
Intracoronary Compared to Intravenous Abciximab and High-Dose Bolus Compared to Standard Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Transradial Primary Percutaneous Coronary Intervention: a Two-by-Two Factorial Placebo-Controlled Randomized Study
2010
Prevention of Venous Thromboembolism
2004 Standout
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis
2013
Novel antiplatelet and antithrombotic activities of essential oil from Lavandula hybrida Reverchon “grosso”
2004
Prevention of Venous Thromboembolism
2008 Standout
Inflammation and thrombosis – testing the hypothesis with anti- inflammatory drug trials
2016
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
2008
Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI
2005
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
Early vs Late Administration of Glycoprotein IIb/IIIa Inhibitors in Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction
2004
Fibrinogen and fibrin: scaffold proteins in hemostasis
2007
Fibrin network structure and clot mechanical properties are altered by incorporation of erythrocytes
2009
Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine
2008 Standout
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Changes in Enoxaparin Pharmacokinetics During Pregnancy and Implications for Antithrombotic Therapeutic Strategy
2008
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
Anti‐factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis
2005
Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE)
2007
A practical guide to hydrogels for cell culture
2016 Standout
Pharmaceutical and therapeutic Potentials of essential oils and their individual volatile constituents: a review
2007 Standout
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
2018 Standout
Enoxaparin Dosing and Associated Risk of In-Hospital Bleeding and Death in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
2007
Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality
2000
Extracellular DNA traps promote thrombosis
2010 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease
2003 Standout
Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans
2002 Standout
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
What Is the Biological and Clinical Relevance of Fibrin?
2016
Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease
2001
The role of inflammation in vascular diseases
2000
Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations
1999
Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency
2006
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
2016 Standout
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
2012
Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings
2009
Guidelines for the Primary Prevention of Stroke
2014 Standout
Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function
2007
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations
1999
The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction
2011 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Platelet-related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis
2014
Mechanisms of fibrin polymerization and clinical implications
2013
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2008 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Racial-Ethnic Disparities in Stroke Care: The American Experience
2011 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Gender-Specific Alterations in Fibrin Structure Function in Type 2 Diabetes: Associations with Cardiometabolic and Vascular Markers
2012
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.
1998 Standout
Works of J.P. Collet being referenced
Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome
2005
Regulation Of Fibrinogen Biosynthesis By Cytokines, Consequences On The Vascular Risk
1996
Disaggregation of In Vitro Preformed Platelet-Rich Clots by Abciximab Increases Fibrin Exposure and Promotes Fibrinolysis
2001
Fibrinogen as a risk factor for coronary heart disease.
1998
Altered Fibrin Architecture Is Associated With Hypofibrinolysis and Premature Coronary Atherothrombosis
2006